Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S B Kaye

Showing results (341-350 of 411) with videos related to

Pageof 42
Sort By:
Cancer Research|February 1, 1993
Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusionD Bissett, A Setanoians, J Cassidy, et al.
BJU International|June 26, 2003
Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatmentG Pentheroudakis, J S De Bono, S B Kaye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2019
A decade of clinical development of PARP inhibitors in perspectiveJ Mateo, C J Lord, V Serra, et al.
International Journal of Cancer|December 1, 1994
Topoisomerase I and II activity in human breast, cervix, lung and colon cancerH L McLeod, F Douglas, M Oates, et al.
Progress in Clinical and Biological Research|January 1, 1988
Potential advances in combination chemotherapy for advanced testicular cancerS B Kaye, G Stoter, D Sleijfer, et al.
British Journal of Cancer|February 1, 1996
Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials GroupA R Hanauske, G Catimel, S Aamdal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2012
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experienceL R Molife, S Alam, D Olmos, et al.
Journal of the National Cancer Institute|November 15, 1995
Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysisD S Murphy, S F Hoare, J J Going, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council reportM H Cullen, S P Stenning, M C Parkinson, et al.
Thorax|September 1, 1986
Short duration combination chemotherapy in the treatment of small cell lung cancerA J Dorward, S W Banham, A W Hutcheon, et al.
Pageof 42

Showing results (341-350 of 411) with videos related to

Sort By:
Pageof 42
Cancer Research|February 1, 1993
Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusionD Bissett, A Setanoians, J Cassidy, et al.
BJU International|June 26, 2003
Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatmentG Pentheroudakis, J S De Bono, S B Kaye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2019
A decade of clinical development of PARP inhibitors in perspectiveJ Mateo, C J Lord, V Serra, et al.
International Journal of Cancer|December 1, 1994
Topoisomerase I and II activity in human breast, cervix, lung and colon cancerH L McLeod, F Douglas, M Oates, et al.
Progress in Clinical and Biological Research|January 1, 1988
Potential advances in combination chemotherapy for advanced testicular cancerS B Kaye, G Stoter, D Sleijfer, et al.
British Journal of Cancer|February 1, 1996
Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials GroupA R Hanauske, G Catimel, S Aamdal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2012
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experienceL R Molife, S Alam, D Olmos, et al.
Journal of the National Cancer Institute|November 15, 1995
Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysisD S Murphy, S F Hoare, J J Going, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council reportM H Cullen, S P Stenning, M C Parkinson, et al.
Thorax|September 1, 1986
Short duration combination chemotherapy in the treatment of small cell lung cancerA J Dorward, S W Banham, A W Hutcheon, et al.
Pageof 42